Gilead stops another CD47 study, this time in acute myeloid leukemia - buff.ly/46riCPc

BridgeBio and Resilience Form Gene Therapy Partnership buff.ly/3Qd3ZtD via Genetic Engineering & Biotechnology News

Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone $ETON buff.ly/45xS1zb via $ETON

Researchers are using CRISPR for more complex diseases such as Alzheimer's. Studies done at UC San Diego, Duke University, and more are using CRISPR to target genes found in properties responsible for the disease. Read more from Andrew Joseph at STAT: bit.ly/44LOmxw

Twist Bioscience, Bayer Enter Antibody Discovery Deal Valued at up to $188 Million buff.ly/3LJR6Ve via @clinicalomics

Cell Therapy for Drug-Resistant Epilepsy a Preclinical Success buff.ly/46FyPA6 via Genetic Engineering & Biotechnology News

Chemogenetics Can Dampen Pain Responses in Lab Tests buff.ly/3tp55t9 via @clinicalomics

A decade later, biotech’s CRISPR revolution is still going strong. I traced the history of gene editing startups and what it means for the future. The result? A deep dive into the schools and scientists who mold the future of medicine. For BioPharma Dive biopharmadive.com/news/crispr-bi…

Sanofi adds another AI alliance, this time for biologics with Baidu CEO’s startup - buff.ly/3trFVtR

Thermo Fisher Scientific to buy Olink in $3.1 billion deal reuters.com/markets/deals/…

Pfizer Expands in Immunology With FDA Approval of New Ulcerative Colitis Drug buff.ly/3FkOLMQ

Better Therapeutics begins rolling out digital app for Type 2 diabetes buff.ly/3ZYlsJi

These Japanese life science firms came to San Diego to study startups buff.ly/3S3eP6t

Aldeyra braces for potential dry eye disease rejection after FDA says more data are necessary - buff.ly/3M7323n

Flipped coins found not to be as fair as thought buff.ly/3tzxYmw via Phys.org

Carl Icahn sues Illumina board members over Grail acquisition - buff.ly/3M7viTk

Seed-stage Bay Area biotechs kick off return of BIO Investor Forum - San Francisco Business Times buff.ly/3M8fMGS via San Francisco Business Times

Oncolytic Virus Improves Survival in Glioblastoma Trial buff.ly/45BGyyn via Genetic Engineering & Biotechnology News

New Cancer Therapy Target Stops Tumor Cells From Sharing Resources buff.ly/3tCcmWK

Roche buys U.S. rights to Roivant bowel disease drug in $7.1 billion deal buff.ly/3Ft8vxH